• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

    3/10/23 4:15:17 PM ET
    $ACOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACOR alert in real time by email
    SC 13D/A 1 p23-1102sc13da.htm ACORDA THERAPEUTICS, INC.
    SECURITIES AND EXCHANGE COMMISSION  
    Washington, D.C. 20549  
       
    SCHEDULE 13D/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*
     

    Acorda Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)
     

    00484M601

    (CUSIP Number)
     
    Shulamit Leviant, Esq.
    c/o Davidson Kempner Capital Management LP
    520 Madison Avenue, 30th Floor
    New York, New York 10022
    (212) 446 4053
     
    With a copy to:
     

    Eleazer Klein, Esq.

    Adriana Schwartz, Esq.

    Schulte Roth & Zabel LLP
    919 Third Avenue
    New York, NY 10022

    (212) 756-2000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     

    March 8, 2023

    (Date of Event Which Requires Filing of This Statement)
     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ¨

     

    (Page 1 of 10 Pages)

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 2 of 10 Pages

     

    1

    NAME OF REPORTING PERSON

    M.H. Davidson & Co.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO (see Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New York

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    51,189

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    51,189

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    51,189

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    0.21%

    14

    TYPE OF REPORTING PERSON

    PN

             

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 3 of 10 Pages

     

     

     

    1

    NAME OF REPORTING PERSON

    Davidson Kempner Partners

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO (see Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New York

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    315,640

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    315,640

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    315,640

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    1.30%

    14

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 4 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    DKIP (Cayman) Ltd II

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO (see Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    682,892

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    682,892

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    682,892

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    2.81%

    14

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 5 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Davidson Kempner International, Ltd.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    OO (see Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    British Virgin Islands

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    753,349

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    753,349

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    753,349

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    3.10%

    14

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 6 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Davidson Kempner Capital Management LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF (see Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    1,803,070

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    1,803,070

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    1,803,070

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    7.41%

    14

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 7 of 10 Pages

     

     

    1

    NAME OF REPORTING PERSON

    Anthony A. Yoseloff

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

    AF (see Item 3)

    5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDING IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ¨
    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    7

    SOLE VOTING POWER

    -0-

    8

    SHARED VOTING POWER

    1,803,070

    9

    SOLE DISPOSITIVE POWER

    -0-

    10

    SHARED DISPOSITIVE POWER

    1,803,070

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON

    1,803,070

    12 CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES ¨
    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    7.41%

    14

    TYPE OF REPORTING PERSON

    IN

             

     

     

     

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 8 of 10 Pages

     

     

    Item 1. SECURITY AND ISSUER
       
      The following constitutes Amendment No. 2 (this “Amendment No. 2”) to the Schedule 13D filed by the undersigned on June 10, 2022 (the “Original Schedule 13D”), as amended by Amendment No. 1 to the Original Schedule 13D, filed by the undersigned on January 23, 2023 (“Amendment No. 1,” together with the Original Schedule 13D and this Amendment No. 2, the “Schedule 13D”), with respect to the shares of Common Stock of Acorda Therapeutics, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 2 amends the Schedule 13D as specifically set forth herein. Capitalized terms used herein and not otherwise defined in this Amendment No. 2 have the meanings set forth in the Schedule 13D.  This Amendment No.  2 amends Items 5(a)-(c), as set forth below.

     

    Item 5. INTEREST IN SECURITIES OF THE ISSUER
       
    Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows:

     

    (a) See rows (11) and (13) of the cover pages to this Schedule 13D for the aggregate number of shares of Common Stock and percentages of the Common Stock beneficially owned by each of the Reporting Persons.  The percentages used in this Schedule 13D are calculated based upon 24,337,814 shares of Common Stock outstanding as of November 10, 2022, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the SEC on November 14, 2022.
       
    (b) See rows (7) through (10) of the cover pages to this Schedule 13D for the number of shares of Common Stock as to which each Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition.
       
    (c) In addition to the transactions set forth in Item 3 above, information concerning transactions in the Common Stock reported herein effected since the filing of Amendment No. 1 is set forth in Schedule A, which is attached hereto and is incorporated herein by reference.  All of the transactions in the Common Stock listed therein were effected in the open market through various brokerage entities.
       

     

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 9 of 10 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE:  March 10, 2023 /s/ Anthony A. Yoseloff
      ANTHONY A. YOSELOFF, (i) individually; (ii) as Executive Managing Member of: (a) Davidson Kempner Capital Management LP, (x) for itself and (y) as Investment Manager of Davidson Kempner International Ltd. and DKIP (Cayman) Ltd II; and (b) Davidson Kempner Liquid GP Topco LLC, as Managing Member of (1) M.H. Davidson & Co. GP, L.L.C., as General Partner of M.H. Davidson & Co. and (2) MHD Management Co. LLC, as General Partner of Davidson Kempner Partners.

     

     

     

    CUSIP No. 00484M601SCHEDULE 13D/APage 10 of 10 Pages

    SCHEDULE A

     

    Transactions in the COMMON STOCK of the Issuer
    SINCE THE FILING OF AMENDMENT NO. 1

     

    The following table sets forth all transactions in the Common Stock effected since the filing of Amendment No. 1 by the Reporting Persons. Except as noted below, all such transactions were effected in the open market through brokers and the price per share is net of commissions. The Reporting Persons undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares of Common Stock purchased at each separate price.

     

     

    Trade Date Shares Purchased (Sold) Price Per Share ($)*
    01/23/2023 (26,648) 1.00
    01/25/2023 (2,000) 1.00
    01/26/2023 (7,720) 1.00
    02/02/2023 (10,829) 1.00
    02/06/2023 (102,280) 1.00
    02/07/2023 (12,022) 1.00
    02/09/2023 (51,302) 0.93
    02/21/2023 (1,440) 0.93
    02/22/2023 (408) 0.93
    03/08/2023 (41,126) 1.00
    03/09/2023 (23,917) 1.01

     

     

     

    *       Excluding commissions, SEC fees, etc. (rounded to nearest cent).

    Get the next $ACOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACOR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Acorda Therapeutics Announces Resignation of Chief Operating Officer

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Lauren Sabella, Chief Operating Officer, will resign from the Company effective September 30, 2022. Ms. Sabella will be working in a strategic advisory role for early-stage biotechnology companies. "We are grateful for Lauren's thirteen years of contributions as a member of Acorda's executive leadership team. Initially, she and her team led the commercial launch of AMPYRA, a novel treatment for multiple sclerosis. The tremendous success of that product allowed Acorda to invest in additional clinical development programs, including INBRIJA for Parkinson's disease," said Ron Cohen, M.D., Acorda's President and CEO. "Lauren has been

      8/19/22 8:00:00 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acorda Therapeutics Announces Delisting from Nasdaq

      Acorda Therapeutics, Inc. today announced that its common stock is no longer listed on the Nasdaq Stock Market. The delisting is a result of the Company's failure to demonstrate compliance with Nasdaq Listing Rules 5101, 5110(b), and IM-5101-1 as a result of the Company's commencement of Chapter 11 proceedings and Nasdaq Listing Rule 5450(b)(1)(A) for failure to maintain stockholders' equity of at least $10 million. Trading in the Company's common stock on the Nasdaq exchange was suspended on April 12, 2024. The Company's common stock is quoted on the OTC Pink® Open Market platform operated by OTC Markets Group Inc. since April 12, 2024 under the "ACORQ" ticker symbol. About Acorda Therap

      4/15/24 5:03:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Announces Nasdaq Delisting Notification

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announcement that it has reached an agreement with Merz Therapeutics to acquire substantially all of the assets of the Company. In connection with that announcement, Acorda and certain of its affiliates filed voluntary petitions to commence Chapter 11 proceedings in the U.S. Bankruptcy Court for the Southern District of New York. Nasdaq commenced proceedings to delist the Company's common stock, based on th

      4/3/24 5:30:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement

      Acorda Files for Voluntary Chapter 11 Protection to Facilitate Orderly Sale Acorda Enters into a Restructuring Support Agreement with over 90% of the Secured Convertible Noteholders Patient Access to INBRIJA® (levodopa inhalation powder) and AMPYRA® (dalfampridine) to Continue Uninterrupted Acorda Therapeutics, Inc. (NASDAQ:ACOR) ("Acorda" or "the Company") today announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to INBRIJA, AMPYRA, and FAMPYRA for $185 million. Merz Therapeutics, a leader in the field of neurotoxins, is a business of the global family-owned company Merz, hea

      4/1/24 6:35:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Burns Thomas M.

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:59:21 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Burns Thomas M.

      3 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 7:57:11 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Varian John

      4 - Acorda Therapeutics, Inc. (0001008848) (Issuer)

      6/23/23 5:38:37 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Acorda Therapeutics Inc.

      10-Q - Acorda Therapeutics, Inc. (0001008848) (Filer)

      5/14/24 8:24:14 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K/A filed by Acorda Therapeutics Inc. (Amendment)

      10-K/A - Acorda Therapeutics, Inc. (0001008848) (Filer)

      4/29/24 8:39:11 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Acorda Therapeutics, Inc. (0001008848) (Filer)

      4/25/24 8:00:48 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Financials

    Live finance-specific insights

    See more
    • Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that it will no longer hold its fourth quarter and year end 2023 earnings conference call originally scheduled for Monday, April 1 at 4:30 p.m. ET. The Company does expect to timely file its Annual Report on Form 10-K for the period ended December 31, 2023. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson's disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor

      4/1/24 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024

      Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: https://events.q4inc.com/attendee/373031481 If you register for the webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the webcast details. On the day of the webcast, you will receive an email 2 hours prior to the start of the webcast with the link to join. The presentation will be

      3/25/24 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Acorda Therapeutics Reports Third Quarter 2023 Financial Results

      INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million Biopas Laboratories files for approval of INBRIJA in six Latin American countries Acorda Therapeutics, Inc. (NASDAQ:ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. "We were pleased to see a 32% increase in new INBRIJA prescription requests in Q3 2023 over Q3 2022. New prescription requests have increased by 38% in the first three quarters o

      11/13/23 4:01:00 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Acorda Therapeutics upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Acorda Therapeutics from Neutral to Buy and set a new price target of $10.00 from $5.00 previously

      6/17/21 6:09:07 AM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ACOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13D/A - Acorda Therapeutics, Inc. (0001008848) (Subject)

      5/10/23 4:37:39 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13D/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

      3/10/23 4:15:17 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Acorda Therapeutics Inc. (Amendment)

      SC 13G/A - ACORDA THERAPEUTICS INC (0001008848) (Subject)

      2/14/23 4:52:06 PM ET
      $ACOR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care